PARP inhibitor monotherapy or combination therapy with other antitumor small molecules is in clinical trials for pancreatic ductal adenocarcinoma (PDAC) patients with BRCA mutations or mutations in other DNA damage repair genes [31]. The gene discussed is PARP1; the disease is pancreatic ductal adenocarcinoma.